SPL5B / SpliSense - LARVOL DELTA

SPL5B an ASO drug reducing MUC5B as a therapeutic approach for reducing mucus plugs in CF (NACFC 2025) - "SPL5B ASOs lead to a specific controlled reduction of MUC5B. In CF patients the reduction of MUC5B levels in the lungs is predicted to improve MCC and induce clearance of lung mucus reducing infections and inflammations providing a clinical benefit to patients."

Immunology • Infectious Disease • Inflammation • MUC5AC • MUC5B

ASOs reducing MUC5AC or MUC5B as a therapeutic approach for CF and other muco-obstructive diseases (ECFS 2024) - "our results demonstrate that SPL5AC and SPL5B ASOs have a potential therapeutic benefit for CF and other muco-obstructive patients with the objective to advance to first in Human in 2024."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • MUC5AC • MUC5B

Reducing MUC5AC or MUC5B expression using antisense oligonucleotides as a therapeutic approach for cystic fibrosis and other muco-obstructive diseases (NACFC 2023) - "SPL5AC and SPL5B ASOs have potential therapeutic benefit in CF and other muco-obstructive diseases, with the objective of advancing to first-in-human trials in 2024."

Asthma • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • MUC5AC • MUC5B